Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Animal Health, Inc. (NASDAQ:JAGX) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 245,697 shares, an increase of 227.7% from the November 30th total of 74,987 shares. Currently, 7.1% of the company’s stock are sold short. Based on an average daily trading volume, of 566,481 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 566,481 shares, the short-interest ratio is currently 0.4 days. Currently, 7.1% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Jaguar Animal Health currently has a consensus rating of “Hold” and a consensus price target of $60.00.

Jaguar Animal Health Stock Performance

Shares of JAGX stock opened at $1.11 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.52 and a debt-to-equity ratio of 4.08. The company’s fifty day moving average price is $1.51 and its 200-day moving average price is $2.03. Jaguar Animal Health has a 12 month low of $1.00 and a 12 month high of $33.25. The stock has a market cap of $4.17 million, a PE ratio of -0.03 and a beta of -0.12.

Jaguar Animal Health (NASDAQ:JAGX) last posted its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($6.28) EPS for the quarter, missing analysts’ consensus estimates of ($5.08) by ($1.20). The firm had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $3.73 million. Jaguar Animal Health had a negative net margin of 341.90% and a negative return on equity of 1,194.94%. On average, equities analysts expect that Jaguar Animal Health will post -0.8 EPS for the current fiscal year.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.